



SAUDI FELLOWSHIP TRAINING PROGRAM

HEMATOLOGY / ONCOLOGY PHARMACY

Final Written Examination

Examination Format:

A Saudi subspecialty fellowship final written examination shall consist of one paper with 80-120 Single Best Answer MCQs. 10% unscored items can be added for pretesting purposes.

Passing Score:

The passing score is 70%. If the percentage of candidates passing the examination before final approval is less than 70%, the passing score must be lowered by one mark at a time aiming at achieving 70% passing rate or 65% passing score whichever comes first. Under no circumstances can the passing score be reduced below 65%.





Suggested References:

1. The American Society of Clinical Oncology (ASCO) and The European Society of Medical Oncology (ESMO) updated guidelines
2. National Comprehensive Cancer Network (NCCN) updated guidelines
3. The American Society of Hematology and The American Society of Transplantation and Cellular Therapy (ASBMT) updated guidelines
4. Infectious diseases in allogenic Hematopoietic Stem Cell Transplantation: Prevention and Prophylaxis Strategy (AGIHO/DGHO) updated guidelines
5. Multinational Association of Supportive Care in Cancer (MASCC) updated guidelines
6. Professionalism and Ethics, Handbook for Residents, Practical guide, Prof. James Ware, Dr. Abdulaziz Fahad Alkaabba, Dr. Ghaiath MA Hussein, Prof. Omar Hasan Kasule, SCFHS, Latest Edition.
7. Essentials of Patient Safety, SCHS, Latest Edition.

Note:

This list includes latest published guidelines before July 2023, and it is intended for use as a study aid only. SCFHS does not intend the list to imply endorsement of these specific references, nor are the exam questions necessarily taken solely from these sources.





Blueprint Outlines:

No.	Sections	Percentage
1	Breast cancer	10%
2	Gastrointestinal cancer	10%
3	Genitourinary cancer	6%
4	Gynecological cancer	7%
5	Head/Neck cancer	5%
6	Hematological diseases ¹	30%
7	Lung cancer	6%
8	Melanomas, Sarcomas	6%
9	Neurooncology	5%
10	Supportive care	15%
Total		100%

- ¹Hematological diseases: including malignant and benign hematological disorders, lymphomas, and bone marrow transplantation.

Note:

- Blueprint distributions of the examination may differ up to +/-5% in each category.
- Percentages and content are subject to change at any time. See the SCFHS website for the most up-to-date information.
- Research, Ethics, Professionalism and Patient Safety are incorporated within various domains.
- Results will be published within 14 business days following the last date of your examination.

